Patent ID: 11952593
Assignee: nan
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  G | IPC C  G

Claim 19:
20. The method of claim 19, wherein, in the in vitro method, the cancer cells isolated from the malignant tumor are cultured in the presence or absence of the compound and at least one anticancer drug for the predetermined period of time; and
the counting numbers of the P1, and/or P1 and P2 cell subgroups and P3 through P8 cell subgroups produced during the predetermined period of time in the presence or absence of the compound and the at least one anticancer drug, wherein a larger proportion of the P1, and/or P1 and P2 cell subgroups of the total number of P1 through P8 cell subgroups in the cancer cells cultured in the presence of the compound and the at least one anticancer drug as compared to the proportion of the P1, and/or P2 cell subgroups of the total number of P1 through P8 cell subgroups in the cancer cells cultured in the absence of the compound and the at least one anticancer drug predicts the compound's ability to inhibit the multinucleate cell production resulting from post-mitotic cell fusion during DNV.